Related Experiment Video
Updated: Sep 23, 2025
06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
9.8K
Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options
T Bieber1,2, A S Paller3, K Kabashima4
1Department of Dermatology and Allergy, University Medical Center, Bonn, Germany.
Summary
Atopic dermatitis (AD) involves complex immune responses and genetics, leading to chronic skin inflammation. New targeted therapies, like JAK inhibitors, offer personalized treatment options for specific AD subtypes.
Area of Science:
- Dermatology
- Immunology
- Molecular Biology
Background:
- Atopic dermatitis (AD) is a chronic, heterogeneous inflammatory skin disease with significant health burden.
- AD presents diverse clinical phenotypes due to complex interactions between genetics, immune dysregulation, and environmental factors.
Purpose of the Study:
- To review the cellular and molecular mechanisms underlying atopic dermatitis.
- To discuss the evolution of treatment strategies from broad immunosuppression to targeted therapies.
Main Methods:
- Review of current literature on atopic dermatitis pathophysiology.
- Analysis of cellular and molecular pathways, including T-cell inflammation and JAK signaling.
- Examination of emerging targeted therapies such as JAK inhibitors and biologics.
Main Results:
- T-cell-driven inflammation, particularly via T helper (Th) 2 and Th17 cytokines mediated by the Janus kinase (JAK) pathway, is critical in AD.
- Inflammatory processes interact with sensory neurons, causing itch, pain, and sleep disturbances.
- Targeted therapies, including JAK inhibitors and biologics, are advancing treatment for AD.
Conclusions:
- Understanding AD's molecular pathways has led to targeted treatments.
- JAK inhibitors and cytokine-specific biologics represent a shift towards personalized medicine for AD subtypes.
- Further research promises individualized treatment strategies tailored to specific patient profiles.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
531
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
531
01:20Asthma: Pathogenesis and Management
656
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
656
01:19Antiasthma Drugs: Leukotriene Modifiers
544
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
544
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:27Allergic Drug Reactions
1.0K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.0K
01:30Hypersensitivities
1.1K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
1.1K